Skip to content

Study · Not a test of the peptide alone · 2015

1 result

Development and Preliminary Evaluation of TFIB, a New Bimodal Prosthetic Group for Bioactive Molecule Labeling.

Billaud EM, Vidal A, Vincenot A, Besse S, Bouchon B, Debiton E, Miot-Noirault E, Miladi I, Rbah-Vidal L, Auzeloux P, Chezal JM

ACS medicinal chemistry letters24 Nov 2014Cited by 2 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cell-free)Other

    Radiolabeled TFIB tagged the tumor-targeting peptides PEG3[c(RGDyK)]2 and NDP-MSH in mild conditions with radiochemical yields of 47-83% and purities above 99%.

    In plain wordsIn lab chemistry, a new radiolabel was attached to two tumor-targeting peptides, including NDP-MSH, with good yields and high purity.

    Outcome
    Not applicableRadiolabeling yield and purity of TFIB-tagged peptides
    Study

    n: not reported in source

    Radiochemical synthesis
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Measurements

    Radiochemical yield
    47 to 83 % d.c.
    TFIB-tagged peptides
    Radiochemical purity
    > 99%
    TFIB-tagged peptides

    Source sentences

    Summary
    Then, radiolabeled [ (125) I]/[ (18) F]TFIB was used to tag tumor-targeting peptides (i.e., PEG3[c(RGDyK)]2 and NDP-MSH targeting αvβ3 integrin and MC1R receptors, respectively) in mild conditions and with good radiochemical yields (47-83% d.c.) and purities (>99%).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.